Factors influencing survival after kidney transplant failure by McCaughan, Jennifer A. et al.
Factors influencing survival after kidney transplant failure
McCaughan, J. A., Patterson, C. C., Maxwell, A. P., & Courtney, A. E. (2014). Factors influencing survival after
kidney transplant failure. Transplantation research, 3(18). DOI: 10.1186/2047-1440-3-18
Published in:
Transplantation research
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2014 McCaughan et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
RESEARCH Open Access
Factors influencing survival after kidney
transplant failure
Jennifer A McCaughan1,2*, Christopher C Patterson3, Alexander P Maxwell1,2 and Aisling E Courtney1
Abstract
Background: The failure of a kidney transplant is now a common reason for initiation of dialysis therapy. Kidney
transplant recipients commencing dialysis have greater morbidity and mortality than transplant-naïve, incident
dialysis patients. This study aimed to identify variables associated with survival after graft failure.
Methods: All recipients of first, deceased donor kidney transplants performed in Northern Ireland between 1986
and 2005 who had a functioning graft at 12 months were included (n = 585). Clinical and blood-derived variables
(age, gender, primary renal disease, diabetic status, smoking status, human leukocyte antigen (HLA) mismatch,
acute rejection episodes, immunosuppression, cardiovascular disease, graft survival, haemoglobin, albumin, phosphate,
C reactive protein, estimated glomerular filtration rate (eGFR), rate of eGFR decline, dialysis modality, and access) were
collected prospectively and investigated for association with re-transplantation and survival. The association between
re-transplantation and survival was explored by modelling re-transplantation as a time-dependent covariate.
Results: Median follow-up time was 12.1 years. Recipients with a failing graft (158/585) demonstrated rapid loss of eGFR
prior to graft failure, reducing the time available to plan for alternative renal replacement therapy. Median survival after
graft failure was 3.0 years. In multivariate analysis, age and re-transplantation were associated with survival after graft
failure. Re-transplantation was associated with an 88% reduction in mortality.
Conclusions: Optimal management of kidney transplant recipients with failing grafts requires early recognition of
declining function and proactive preparation for re-transplantation given the substantial survival benefit this confers.
The survival benefit associated with re-transplantation persists after prolonged exposure to immunosuppressive therapy.
Keywords: Kidney transplantation, Survival, Graft failure, Re-transplantation
Background
The proportion of the incident dialysis population with a
failed kidney transplant is increasing each year [1,2].
Despite advances in kidney transplantation which have
substantially reduced the rate of early graft loss, the im-
pact on long-term graft survival has been disappointing
[3,4]. The morbidity and mortality of kidney transplant
recipients commencing dialysis are high [5-11].
Transplant recipients receive intensive supervision from
nephrologists following transplantation and review con-
tinues throughout the lifespan of the transplant, albeit at a
reduced frequency. It is reasonable to anticipate that these
individuals should receive optimal care with regard to
management of the complications of progressive chronic
kidney disease (CKD) and planning for dialysis. The avail-
able evidence suggests that this is not the case. Markers of
anaemia, nutrition, inflammation, and mineral bone dis-
ease are reportedly worse in the failed renal transplant
population than in transplant-naïve patients at the initi-
ation of dialysis [7,12-14]. This is despite the fact that one
quarter of the incident dialysis population are not known
to a nephrologist more than 1 month prior to commen-
cing dialysis therapy [15].
Kidney transplant failure has ramifications for both
transplant recipients and healthcare providers. While
there is evidence that there may be sub-optimal manage-
ment of transplant recipients in the pre-dialysis period,
limited data has been published to highlight which
modifiable clinical parameters are associated with sur-
vival following graft failure. We aimed to address this
issue in our study.
* Correspondence: jamccaughan@doctors.org.uk
1Regional Nephrology Unit, Belfast City Hospital, Belfast BT9 7AB, UK
2Nephrology Research Group, Queen’s University, Belfast BT9 7AB, UK
Full list of author information is available at the end of the article
TRANSPLANTATION 
RESEARCH
© 2014 McCaughan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
McCaughan et al. Transplantation Research 2014, 3:18
http://www.transplantationresearch.com/content/3/1/18
Patients and methods
Patient cohort
All recipients of first, deceased donor transplants under-
taken between 1986 and 2005 in Northern Ireland who
had self-supporting graft function at 12 months were in-
cluded. Recipients with graft failure within the first year
were excluded as they defaulted to their pre-transplant
dialysis modality without a prodromal period during
which CKD complications could be managed and prepa-
rations made for alternative renal replacement therapy
(RRT). Individuals whose grafts failed during follow-up
at another centre or who returned to dialysis following
urgent graft nephrectomy were also excluded. Recipients
were followed up until death or August 1, 2012.
Transplant data
Clinical data for all recipients and donors is prospect-
ively collected; recorded variables include age, gender,
primary renal disease, diabetic status, smoking status,
human leukocyte antigen (HLA) mismatch, immunosup-
pression, acute rejection episodes, cardiovascular disease,
graft survival, mode of RRT at graft failure, recipient
survival, and cause of death. Primary renal disease is
grouped into six categories: glomerulonephritis, chronic
pyelonephritis/tubulointerstitial disease, autosomal dom-
inant polycystic kidney disease, diabetic nephropathy,
other specified etiologies, and CKD not defined. The
diagnosis of cardiovascular disease necessitates physician
documentation and objective evidence; for example, a
diagnosis of “myocardial infarction” would require clinical
documentation with a corresponding electrocardiogram,
elevation in cardiac enzymes, or record of confirmatory
angiography.
Graft failure data
Graft failure was defined as the commencement of an
alternative mode of RRT. Clinical and blood-derived
parameters from the date of graft failure were obtained
from a combination of patient records, the laboratory re-
sults system, and the regional renal database (a prospect-
ive clinical database maintained by nephrologists).
Clinical information was collected on dialysis modality
and type of access for dialysis: temporary catheter, tun-
nelled catheter, polytetrafluoroethylene (PTFE) graft, ar-
teriovenous fistula (AVF), or peritoneal dialysis catheter.
Estimated glomerular filtration rate (eGFR) at the initi-
ation of dialysis therapy was calculated using the four-
variable MDRD equation [16]. The rate of decline in eGFR
prior to graft failure was calculated by least squares linear
regression using a minimum of six values obtained at four
monthly intervals.
Serum haemoglobin, phosphate, albumin, and C react-
ive protein concentrations were recorded within 1 month
of graft failure.
Statistical analysis
In the analysis of graft survival, the factors included in
Cox regression analysis were recipient age, primary renal
disease, donor age, era of transplantation, HLA mis-
match, biopsy-proven acute rejection within 6 months,
and type of maintenance immunosuppression.
In the analysis of patient survival, re-transplantation
was included as a time-dependent covariate in a Cox’s
proportional hazards model. In this model, patients
contribute follow-up to the “no re-transplantation” group
prior to re-transplantation and then switch to the “re-
transplantation” group once a second transplant has oc-
curred. If there is subsequent failure of the re-transplant,
follow up continues in the latter group. This model
reduces the statistical bias which occurs in a standard
Cox’s proportional hazard model. For pre-emptive re-
transplants, the time to re-transplantation was recorded as
0. Factors included in multivariate analysis were recipient
age, gender, primary renal disease, diabetes mellitus, car-
diovascular disease, smoking status, anaemia, hyperpho-
sphatemia, and mode of RRT.
Time to re-transplantation was also analysed using the
Cox’s proportional hazards model with death considered
as a competing risk. This method is used when follow-
up for the outcome of interest (re-transplantation) is no
longer possible because of the occurrence of a compet-
ing event (death) [17].
SPSS version 20 (SPSS Inc., Chicago, IL) was used for
univariate analyses. Stata release 11 (StataCorp, College
Station, TX) was used for time-dependent covariate and
competing-risks survival time analyses.
Ethics statement
Ethical approval for this study was granted by the Regional
Ethics Committee (12/NI/0178).
Results
Patient demographics
There were 707 first, deceased donor kidney transplants
performed between 1986 and 2005. Twelve months after
transplantation, 585 recipients had functioning grafts;
the demographics of this population are reported in
Table 1. Prednisolone and azathioprine was the routine
dual immunosuppressive therapy in this centre until
1989 when calcineurin inhibitors (CNI) were introduced;
CNI-free maintenance regimens were employed in 25%
of the recipients. No induction therapy was used during the
study period. The median follow-up time was 12.1 years
(range 1–26 years).
Graft failure
There were 162 cases of death-censored graft failure; the
median graft survival was 10.4 years (range 1–26 years).
Transplant biopsies were performed on 99 recipients
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with subsequent death-censored graft failure; 10% had
late acute rejection, 3% had chronic immunological in-
jury, 23% had interstitial fibrosis/tubular atrophy attrib-
uted to CNI toxicity, 22% had recurrence of their
primary renal disease, 31% had another histological diag-
nosis, and 11% were non-diagnostic. Two individuals
with graft failure which occurred during follow-up in
another centre were not included in further analyses.
A further two individuals were excluded because they
required urgent graft nephrectomy, one for renal cell
carcinoma and the other for refractory malignant hyper-
tension, while maintaining self-supporting graft function
(Figure 1). The median follow-up time after graft failure
was 4.8 years (range 0–21.8 years).
In multivariate analysis, acute rejection (HR 2.2, p <
0.001), donor age (HR 1.2 (per decade), p = 0.001), and
calcineurin inhibitor-based immunosuppression (HR 2.2,
p = 0.003) were strongly associated with graft failure.
Renal replacement therapy
Estimated GFR
The eGFR at commencement of alternative RRT was re-
corded for 143/158 (91%) individuals. The mean eGFR
was 9.8 mL/min/1.73 m2 (SD 3.9 mL/min/1.73 m2). The
mean annual loss of eGFR prior to graft failure was
7.9 mL/min/1.73 m2 (95% CI 7.0–8.8 mL/min/1.73 m2).
Dialysis: modality and access
Following graft failure, 154 recipients returned to dialy-
sis therapy and four had pre-emptive transplants. The
majority of patients (70%) commenced haemodialysis
(Table 2); dialysis modality was unrecorded for nine re-
cipients who died prior to 1997. The haemodialysis co-
hort was older than the peritoneal dialysis group (45.6 vs
35.8 years, p = 0.002), but the prevalence of diabetes
mellitus (7% vs 3%, p = 0.47) and cardiovascular disease
(44% vs 33%, p = 0.32) was comparable between the mo-
dalities. Almost half of all recipients who started haemo-
dialysis did so with a temporary catheter. All 31 (34%)
recipients with a functioning AVF had had this formed
prior to transplantation. The annual loss of eGFR prior
to graft failure did not differ between recipients who
recommenced dialysis via a temporary catheter and
those with alternative access (p = 0.61).
Haematological and biochemical parameters
Serum haemoglobin, phosphate and albumin concentra-
tions, and the percentage of individuals attaining K/
DOQI targets for CKD5 are shown in Table 3. There
were just over a quarter of recipients with haemoglobin,
and a fifth with a serum phosphate concentration, in the
desired range.
Immunosuppression
Immunosuppression was reduced within 12 months fol-
lowing graft failure in 89% of the recipients; 18% were
completely weaned from immunosuppressive drugs.
Reduction in immunosuppression was not associated
with re-transplantation (p = 0.7). Graft nephrectomy is
not routinely practised but was undertaken in two recip-
ients in the context of refractory acute rejection; one in-
dividual had immunosuppression stopped immediately
following nephrectomy, while the other was maintained
on low dose prednisolone. These individuals are highly
sensitised and both have wait-listing times for re-
transplantation exceeding 84 months.
Re-transplantation
There were 56 (35%) patients re-transplanted within
the follow-up period; 16 were living donor transplants.
The median time to re-transplantation was 27 months
(range 0–164 months).
In a univariate competing risks model, older age (HR 0.7
(per decade), p <0.001), cardiovascular disease (HR 0.5,
p = 0.01), diabetes mellitus (HR 0.4, p = 0.03), and com-
mencing dialysis with a temporary catheter (HR 0.5,
p = 0.03) were associated with reduced likelihood of re-
transplantation. There was no significant association
Table 1 Demographics of 585 recipients in the study
population
Variable n
Recipient variables
Age, mean (SD), years 41 (16.5)
Male gender 372 (64%)
Primary renal disease
Glomerulonephritis 121 (21%)
Chronic pyelonephritis/tubulointerstitial disease 119 (20%)
Autosomal dominant polycystic kidney disease 88 (15%)
Chronic kidney disease—not specified 77 (13%)
Diabetic nephropathy 53 (9%)
Other specified etiologies 127 (22%)
Donor variables
Age, mean (SD), years 36 (16.5)
Male gender 343 (59%)
Transplant variables
Decade of transplantation
1986–1995 303 (52%)
1996–2005 282 (48%)
HLA mismatch, mean (SD), no. of antigens 2.2 (1.1)
Ischaemic time, mean (SD), minutes 1,426 (442)
Acute rejectiona 108 (19%)
CNI-based immunosuppression 461 (79%)
aBiopsy-proven acute rejection within 6 months.
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between HLA mismatch at first transplant (HR 0.9, p =
0.11), eGFR at graft failure (HR 0.9, p = 0.20), rate of
eGFR decline (HR 1.0, p = 0.32), commencing periton-
eal dialysis (HR 1.5, p = 0.20), serum haemoglobin (HR
1.0, p = 0.98), serum phosphate (HR 0.8, p = 0.46), or
serum albumin (HR 1.0, p = 0.70). In a Cox regression
model, only age (HR 0.71, CI 0.55–0.91) remained as-
sociated with re-transplantation; the median age at
graft failure in recipients who were re-transplanted
was 35 years compared to 52 years in those who did
not receive a second graft.
Recipient survival
There were 65 (41%) deaths within the follow-up period;
the median survival time for these recipients after graft
failure was 3.0 years and the median age at death was
Figure 1 Identification of the study cohort.
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62 years. The cause of death was unknown for four indi-
viduals; 46% (n = 28) of the remaining deaths were at-
tributable to cardiovascular disease, 18% (n = 11) to
infection, 15% (n = 9) to malignancy, and the remaining
21% to miscellaneous causes including renal failure (n =
5), sudden cardiac arrest (n = 3), venous thromboembol-
ism (n = 3), respiratory failure secondary to chronic pul-
monary disease (n = 1), and haemorrhage (n = 1). For
comparison, the causes of death for recipients with func-
tioning grafts were analysed: 29% were attributable to
cardiovascular disease, 22% to malignancy, and 21% to
infection. In univariate analysis, diabetes mellitus, car-
diovascular disease, higher eGFR, and commencing
haemodialysis were associated with mortality; these asso-
ciations were lost after adjustment for confounders.
Ascertainment of targets for serum haemoglobin and
phosphate at graft failure was not associated with sur-
vival. Multivariate analysis demonstrated that recipient
age and re-transplantation were strongly associated with
survival (Table 4).
Discussion
Kidney transplantation is transformational for the recipi-
ent and cost effective for the healthcare provider [18,19].
There has been notable progress over the past two de-
cades with 1-year death-censored graft survival improv-
ing from 85% to 96% [3]. Despite this, a solitary kidney
transplant is unlikely to meet the lifelong needs of many
recipients, and the number of individuals awaiting re-
transplantation has doubled since 1990. This group
currently comprise over 15% of the transplant waiting
list [20,21].
Kidney transplant recipients returning to dialysis have
significantly reduced survival compared to both the
transplant-naïve dialysis population and those with func-
tioning renal grafts [5-11]. This is predictable given that
this population has acquired the detrimental effects of
long-term immunosuppression and also the increased
risks associated with a second period of progressive
CKD. Cardiovascular disease accounted for 46% of
deaths in this cohort. In a study of recipients with failed
transplants using USRDS registry data, cardiovascular
disease was also the leading cause of death [22]. A
greater proportion of deaths in recipients after graft fail-
ure were attributable to cardiovascular disease compared
to individuals with functioning transplants. This may
reflect the prolonged period of CKD, with associated
classical and non-classical cardiovascular risk factors,
combined with decreased exposure to immunosuppres-
sion. The practice in our centre is to minimise immuno-
suppression following graft failure which may attenuate
the development of life-threatening infection and malig-
nancy in this population and explain the reduced pro-
portion of infection and cancer-related deaths.
Re-transplantation was the only clearly modifiable fac-
tor in this analysis which improved the survival of recip-
ients with kidney transplant failure; after adjustment for
multiple covariates, re-transplantation was associated
with an 88% reduction in mortality. While this appears
intuitive, analysis of the impact of re-transplantation on
survival is complex due to the potential confounding
from variables which simultaneously influence the likeli-
hood of re-transplantation and survival. It is also essen-
tial to model re-transplantation as a time-dependent
covariate in this analysis because of the influence of sur-
vival itself on the likelihood of re-transplantation. To the
best of our knowledge, this is the first report of the impact
of re-transplantation in a cohort with kidney transplant
failure who had long-term graft survival and follow-up.
Ojo et al. reported a significant survival benefit from re-
transplantation using similar analysis in a population of
kidney transplant recipients with a median graft survival
of 1.4 years and follow-up time of 3.8 years [22]. In the
modern era, when average death-censored graft survival
following kidney transplantation exceeds 10 years [23], the
finding that the survival benefit of re-transplantation
Table 2 Renal replacement therapy and access modality
at graft failure
Mode of RRT Access type n Percentage
Haemodialysis 111 70
Temporary catheter 48
Arteriovenous fistula 31
Tunnelled catheter 28
PTFE graft 1
Unknown 3
Peritoneal dialysis Peritoneal dialysis catheter 34 22
Transplant Not applicable 4 3
Unknown 9 6
Table 3 Haematological and biochemical parameters at graft failure
Variable na Mean SD K/DOQI target Attained target
Haemoglobin (g/L) 141 (89%) 93 20 100–115 27%
Phosphate (mmol/L) 131 (83%) 1.93 0.59 1.13–1.78 21%
Albumin (g/L) 128 (81%) 33.3 6.5 - -
aNumber of participants for whom values were available and percentage of total cohort.
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persists despite a prolonged exposure to immunosuppres-
sion and CKD is of clear clinical relevance.
Re-transplantation is invariably challenging in this
group as these individuals present both technical and
immunological difficulties. Transplant recipients may ex-
hibit a more rapid loss of kidney function in the months
prior to ESRD than the transplant-naïve CKD population
[24]. This study demonstrates that the median survival
time after commencing dialysis is short, and presumably,
the window of opportunity for transplantation is shorter
again; this, combined with the rapidity of decline in graft
function prior to transplant failure, necessitates a degree
of urgency in the management of these recipients.
Over the past 40 years, 13% of kidney transplants per-
formed at this centre have been re-transplants. This is
comparable to the re-transplantation prevalence else-
where [25]. In this study, 57 recipients with failed grafts
were re-transplanted; these individuals were younger,
had a reduced incidence of diabetes mellitus and cardio-
vascular disease, and were more likely to commence dia-
lysis with permanent access than those who did not
receive a second transplant. There were proportionally
more living donor re-transplants than first transplants in
this centre during the same period. Living donation offers
high-quality kidneys and the opportunity for planned, pre-
emptive re-transplantation [3]. Recipients with failing
grafts are likely to have families who have witnessed the
transformational impact of transplantation. These individ-
uals may be motivated to donate a kidney, and this option
should be pursued at an early stage.
Evidence is accumulating that management of CKD
complications is unsatisfactory in transplant recipients
with graft failure. In this study, targets for the manage-
ment of anaemia and CKD mineral bone disease were
not met. There was no evidence, however, that this influ-
enced the likelihood of re-transplantation or survival.
Additionally, the dialysis modality of choice for persons
with a failed graft is unknown; 71% of patients in this
cohort commenced haemodialysis. This is the largest
study to compare survival outcomes between the dialysis
modalities [26,27]. There was a trend towards improved
survival in the peritoneal dialysis group, but this did not
persist after multivariate analysis. This reflects other
published work where an initial association between
peritoneal dialysis and improved outcomes in transplant
recipients has also been lost after adjustment for covari-
ates [28,29].
Strengths and limitations
Comprehensive clinical follow-up over 25 years is the
first strength of this study. The low level of emigration
from Northern Ireland creates an ideal environment for
research into long-term transplant outcomes. Secondly,
the wealth of prospectively collected data available al-
lows detailed analysis of factors influencing both re-
transplantation and survival and facilitates the investiga-
tion of how parameters at the time of transplant failure
are associated with outcomes. Thirdly, the quantification
of the effect of re-transplantation on recipient survival
in a cohort with a median graft survival exceeding
10 years is novel and relevant. This is the largest study
to date with detailed long-term follow-up of recipients
with failed transplants.
The small number of recipients could be considered a
limitation of this work. While this research lacks the
power of a large, registry-based analysis, the detailed and
comprehensive follow-up allows meaningful conclusions
to be drawn. Secondly, as a result of the historic nature
of this cohort, the mean age of the recipients is younger
than in the present day. However, it is these individuals
who are likely to experience graft failure and require a
subsequent kidney transplant during their lifetime. In
addition, the maintenance immunosuppressive regimen
in the study period is not typical of the modern era. It is
possible that recipients with graft failure who were
transplanted in a later period may have higher rates of
infection and cancer due to a greater cumulative im-
munosuppressive burden with the use of CNI and induc-
tion therapy. Thirdly, information on hypertension and
blood pressure control was not consistently available for
recipients during the follow-up period. This may have
an impact on graft and recipient survival.
Conclusion
The substantial progress in kidney transplantation over
the past 30 years has enhanced both graft and recipient
survival. However, the latter often exceeds the former,
and it is increasingly common for transplant recipients
to return to dialysis therapy. These individuals are
young, have significant comorbidities, and their outcome
on dialysis is poor.
There are many factors which influence survival after
graft failure; some of these are predetermined, such as
age, but others may be modified with strategies to min-
imise and manage complications in transplantation. The
single factor which substantially improves survival and
which is, at least partly, within the domain of the neph-
rologist to influence is re-transplantation. Improving
Table 4 Cox regression analysis for recipient survival
after graft failure
Variable Hazard ratio 95% CI p value
Recipient agea 1.5 1.3–1.9 <0.001
Re-transplantationb 0.16 0.06–0.48 0.001
Cardiovascular disease 1.4 0.8–2.6 0.3
Diabetes mellitus 1.3 0.6–2.5 0.5
aPer decade.
bModelled as a time-dependent covariate.
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outcomes for recipients with failed kidney transplants
requires early recognition of inevitable graft failure, as-
sessment and optimisation of comorbid conditions, in-
vestigation of the possibility of living kidney donation,
and timely re-transplantation if feasible.
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